American journal of cancer research最新文献

{"title":"Neural mechanisms of CALM intervention to improve CRCI in breast cancer survivors: an fMRI-based study.","authors":"Chen Gan, Jian Xu, Senbang Yao, Xinyi Zheng, Longyu Hu, Meiwen Ling, Mingjun Zhang, Huaidong Cheng","doi":"10.62347/OOVH5568","DOIUrl":"https://doi.org/10.62347/OOVH5568","url":null,"abstract":"<p><strong>Background: </strong>Managing Cancer and Living Meaningfully (CALM) intervention's impact on chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors (BCs) was investigated through resting-state functional magnetic resonance imaging (rs-fMRI) to elucidate the underlying neural mechanisms involved.</p><p><strong>Methods: </strong>68 BCs were randomly assigned to either the CALM group (33 patients) or the care-as-usual (CAU) group (35 patients). Cognitive function was assessed before and after the intervention in both groups using the Mini Mental State Examination (MMSE) scale. Pre- and post-intervention rs-fMRI data were also collected for regional homogeneity (ReHo) and functional connectivity (FC) analyses in the CALM group. A total of 68 BCs were randomly assigned to either the CALM group (n = 33) or the care-as-usual (CAU) group (n = 35). Cognitive function was evaluated pre- and post-intervention using the Mini-Mental State Examination (MMSE). In the CALM group, rs-fMRI data were acquired before and after the intervention to assess alterations in regional homogeneity (ReHo) and functional connectivity (FC).</p><p><strong>Results: </strong>CALM intervention demonstrated a greater enhancement in cognitive function compared to CAU (<i>P</i> = 0.004). Following CALM, ReHo exhibited an increase in bilateral occipital and temporal regions, including the superior, middle, and inferior occipital gyri, lingual gyrus, as well as the middle and superior temporal gyri, while a decrease was observed in frontal and cingulate regions, including the bilateral middle, medial, and dorsolateral superior frontal gyri, anterior cingulate and paracingulate gyri, precuneus, posterior cingulate, and left angular gyrus. FC analysis revealed diminished connectivity between the middle frontal gyrus and occipital/calcarine regions, whereas connectivity strengthened with the left anterior cingulate/paracingulate and right orbital frontal regions. ΔMMSE exhibited a positive correlation with ReHo in the left middle frontal gyrus (<i>r</i> = 0.355, <i>P</i> = 0.042) and a reduction in middle frontal-occipital FC (left calcarine: <i>r</i> = 0.353, <i>P</i> = 0.044; right/left middle occipital: <i>r</i> = 0.388/0.423, <i>P</i> = 0.029/0.014).</p><p><strong>Conclusion: </strong>CALM intervention mitigates CRCI in BCs, with the middle frontal gyrus may play a critical.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1733-1746"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cells.","authors":"Jennifer G Haag, Xiaochang Shen, Nikita Sinha, Shuning Chen, Boer Deng, Haomeng Zhang, Catherine John, Wenchuan Sun, Michael Emanuele, Chunxiao Zhou, Victoria Bae-Jump","doi":"10.62347/LIZG3616","DOIUrl":"https://doi.org/10.62347/LIZG3616","url":null,"abstract":"<p><p>Uterine serous carcinoma (USC) belongs to the non-endometrioid subtype of endometrial cancer that is known for its highly aggressive behavior and poor prognosis, highlighting the warrant of novel strategies for the treatment of USC. PLK1 is a type of serine/threonine kinase that is crucial for controlling the progression of the cell cycle, DNA damage response, and genome stability. Targeting PLK1 exhibits potent anti-tumorigenic activity in pre-clinical models of multiple cancer types, and several PLK1 inhibitors have shown significant clinical benefit and favorable safety profiles alone or in combination with other chemotherapeutic agents. Onvansertib is an oral, selective PLK1 inhibitor that exhibits anti-proliferative activity in multiple types of cancer cell and animal models and has demonstrated clinical activity and a favorable safety profile in recent clinical trials. Hence, we investigated the anti-tumorigenic effects of onvansertib in USC cell lines. Nanomolar concentrations of onvansertib significantly inhibited cellular proliferation, led to cell cycle G2 arrest, induced cellular stress and apoptosis, caused DNA damage, and reduced cell adhesion and invasion in ARK-1 and SPEC-2 cells. The combination of onvansertib with paclitaxel demonstrated a synergistic effect in cell proliferation inhibition via inducing cell apoptosis and DNA damage. Our results provide preclinical evidence that onvansertib may be an effective strategy to treat USC and deserves further evaluation in animal models and clinical trials.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1719-1732"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between the tumor microenvironment of hepatocellular carcinoma - including cancer-associated fibroblasts and tumor-associated macrophages - and apparent diffusion coefficient.","authors":"Yu Saito, Yuji Morine, Shinichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Mitsuo Shimada","doi":"10.62347/ZGGJ9531","DOIUrl":"https://doi.org/10.62347/ZGGJ9531","url":null,"abstract":"<p><p>The tumor microenvironment is critical for the acquisition of tumor malignancy in various cancer types. The objectives of this study were to investigate whether the levels of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) reflect the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy (Hx) and to determine whether the apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) reflects CAF and TAM expression. The study cohort comprised 109 patients who underwent initial curative resection for HCC. Alpha smooth muscle actin (αSMA) was selected as a CAF marker and CD204 as a TAM marker. Protein expression was immunohistochemically evaluated in the intratumoral regions of resected specimens. Clinicopathological factors, including the long-term prognosis after Hx, were investigated between αSMA-negative and -positive tumors and between CD204-negative and -positive tumors. The correlation between CAF/TAM marker expression and the calculated minimum ADC using DWI was also evaluated. αSMA-positive expression was correlated with tumor number, invasive growth pattern, and advanced stage. CD204-positive expression was correlated with the presence of venous invasion. Both αSMA-positive expression and CD204-positive expression were significant prognostic factors in the univariate analysis of overall survival and disease-free survival. αSMA/CD204 double positivity was associated with an extremely poor prognosis after Hx and was a significant independent prognostic factor for overall survival (<i>P</i>=0.02, hazard ratio: 3.27). Patients with double positivity also showed a significantly higher ADC^low rate (83%). In conclusion, expression of both CAF and TAM markers reflected a poor prognosis after Hx. Furthermore, the preoperative ADC could be a clinical surrogate marker in the tumor microenvironment in patients with HCC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1747-1758"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial remodeling in osteosarcomas: insights from patient samples and in vitro studies.","authors":"Mélanie Legrand, Sarah Renault, Gonzague de Pinieux, Clara Bourreau, Régis Brion, Louis-Romée Le Nail, Stéphanie Blandin, Philippe Hulin, Franck Verrecchia, Françoise Rédini, Valérie Trichet, Isabelle Corre","doi":"10.62347/KYFO6159","DOIUrl":"https://doi.org/10.62347/KYFO6159","url":null,"abstract":"<p><p>Osteosarcomas (OS) are the most frequent malignant primary bone sarcomas with an overall poor prognostic for high-risk patients. The current therapeutic management combining chemotherapy and surgery remains partially inefficient. OS are very heterogeneous tumors, evolving in a complex and specific highly vascularized microenvironment. Upon microenvironmental signals, remodeling of tumor vessels may occur through angiogenic processes but also through endothelial differentiation process namely the endothelial-to-mesenchymal transition (EndoMT). In a patient cohort of ten high-grade OS samples (at diagnosis, after surgery, and/or metastasis), we detected by a multiplexing immunohistochemistry approach the presence of endothelial cells co-expressing endothelial CD31/EMCN and mesenchymal ASMA/FSP1 markers. In order to partially mimic an OS microenvironment in vitro, we exposed human umbilical vein endothelial cells (HUVECs) to secreted factors of OS tumor or stromal cells. In this cellular model, we established that the secretome from stromal cells did not induce EndoMT in primary ECs. Nevertheless, soluble factors from the OS cell line KHOS were able to induce in ECs some of the EndoMT hallmarks such as induction of mesenchymal markers associated to increased migration, but without inhibition of tubulogenesis. In conclusion, this study identified the presence of endothelial-mesenchymal cells in the tumor microenvironment of OS patients and give cues for further investigation of the regulation and consequences of this remodeling in the biology of OS.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1629-1646"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting cancer-induced skeletal damage: a holistic approach to understanding pathophysiology, mechanisms, and management solutions.","authors":"Xinyi Gu, Dejian Xiang, Haozhong Zhu, Xiaoqian He, Chenhui Yang, Rongjin Chen","doi":"10.62347/QFHJ2430","DOIUrl":"https://doi.org/10.62347/QFHJ2430","url":null,"abstract":"<p><p>Cancer's insidious reach extends far beyond its initial site, particularly manifesting in the skeleton, where it precipitates a spectrum of pathological conditions ranging from bone metastases and cachexia to primary bone cancers. This review highlights the critical impact of cancer on skeletal health, including the development of bone metastases, cachexia, and primary bone cancers, underscoring the importance of understanding the complex interaction between cancer and the bones. It emphasizes the global burden of cancer and its skeletal complications, which severely affect quality of life. The article reviews the prevalence of bone metastases in various cancers, such as breast, prostate, lung, renal cancers, and multiple myeloma, and stresses the need for targeted treatments. It also discusses the mechanisms behind tumor spread to bones and the systemic effects of cancer, including reduced bone mineral density and increased fracture risk, even without direct bone invasion. The challenges posed by primary bone cancers, which are rarer but highly aggressive, are also examined, highlighting the role of genetics and molecular research in treatment development. The review calls for a multidisciplinary approach to manage the severe symptoms of cancer-induced bone damage and explores the potential of personalized medicine to improve treatment outcomes. It concludes by advocating for continued research and collaboration to develop more precise and personalized therapies for cancer-related bone issues, aiming to improve the lives of those affected.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1494-1516"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value, biological role, and mechanisms of LCN2 in childhood acute lymphoblastic leukemia.","authors":"Xue Tang, Yuan-Yuan Li, Lin-Jun Tan, Ju Gao, Zhi-Gui Ma, Xia Guo, Ling Gu, Han-Min Liu","doi":"10.62347/ASRB7620","DOIUrl":"https://doi.org/10.62347/ASRB7620","url":null,"abstract":"<p><p>Resistance to glucocorticoids (GC) is associated with poor prognosis in childhood acute lymphoblastic leukemia (ALL). Lipocalin 2 (LCN2) plays a pro-tumorigenic role in solid tumors and chronic myeloid leukemia by promoting initiation, invasion, metastasis and drug resistance, and has gained increasing attentions as a therapeutic target. However, ALL cells show a low expression status of LCN2. Meanwhile, the clinical significance and biological role of LCN2 remain unclear in childhood ALL. Therefore, we collected bone marrow, peripheral blood, and cerebrospinal fluid samples from children with ALL and control individuals to assess LCN2 expression. Lentiviral transduction was used to establish stable LCN2 overexpression in Nalm6, CEM-C1, CEM-C7, and Molt4 cell lines. The cell growth, proliferation, cell cycle, apoptosis, ferroptosis, and sensitivity to dexamethasone were detected to clarify the function of LCN2. Compared with healthy individuals, non-tumor patients and intracranial solid tumors, LCN2 expression was down-regulated in patients with childhood ALL at diagnosis. Lower LCN2 expression in the bone marrow was associated with poor prognostic features and a lower disease relapse-free rate. Effective chemotherapy could restore the expression of LCN2. Overexpression of LCN2 led to an inhibition of cell growth and an induction of ferroptosis in GC sensitive ALL cells (Nalm6 and CEM-C7), and reversed GC resistance by up-regulating the expression of glucocorticoid receptor (GR) and phosphorylated-GR (p-GR) and inhibiting the Notch signaling pathway. On the contrary to solid tumors, our results suggest that inducing the expression of LCN2 might be a novel therapeutic protocol in childhood ALL.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1759-1776"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune evasion and resistance in breast cancer.","authors":"Ebaa Ababneh, Sarah Velez, Jihe Zhao","doi":"10.62347/PNGT6996","DOIUrl":"https://doi.org/10.62347/PNGT6996","url":null,"abstract":"<p><p>Breast cancer (BC) is the most common malignancy in females with an increasing incidence in the last decade. The previously observed decline in BC mortality rates has also slowed down recently with an increase in the incidence of invasive BC. BC has various molecular subtypes. Among these subtypes, triple-negative breast cancer (TNBC) represents the most aggressive BC, with a poor prognosis. Because lack of the hormonal or human epidermal growth factor receptor 2 (HER2) receptors, TNBC is resistant to hormonal and HER2 targeted therapy effective for other BC subtypes. The good news is that TNBC has recently been considered an immunologically 'hot' tumor. Therefore, immunotherapy, particularly immune checkpoint inhibitor therapy, represents a promising therapeutic approach TNBC. However, a considerable percentage of patients with TNBC do not respond well to immunotherapy, indicating that TNBC seems to adopt several mechanisms to evade immune surveillance. Thus, it is crucial to investigate the mechanisms underlying TNBC immune evasion and resistance to immunotherapy. In this review, we examine and discuss the most recently discovered mechanisms for BC, with a particular focus on TNBC, to evade the immune surveillance via kidnapping the immune checkpoints, suppressing the immune responses in tumor microenvironment and inhibiting the tumor antigen presentation. Evaluation of these mechanisms in BC will hopefully guide future immunotherapeutic research and clinical trials.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1517-1539"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long noncoding RNA VPS9D1-AS1 promotes angiogenesis in colorectal cancer by regulating the VEGFA signalling pathway.","authors":"Zheying Zhang, Yifei Han, Yang Yang, Xianglong Li, Yifan Han, Shuai Zhang, Yan Zou, Yu Zhang, Yitian Xie, Ying Sun, Jiateng Zhong, Baoshun Du, Shenglei Li, Na Li","doi":"10.62347/BKUV1210","DOIUrl":"https://doi.org/10.62347/BKUV1210","url":null,"abstract":"<p><p>To clarify the mechanism of long non-coding RNA VPS9D1-AS1 affecting angiogenesis in colorectal cancer (CRC). Western blot and qRT-PCR assays were performed to detect the expression of VPS9D1-AS1 in colorectal cancer. The effects of VPS9D1-AS1 regulating VEGFA and affecting the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVECs) were examined using cell biology, in vitro tubeformation and Chorioallantoic membrane vascular assay. Chromatin Immunoprecipitation (ChIP) and dual luciferase assays were performed to verify the specific sites of transcription factor binding to the promoter region of VPS9D1-AS1. VPS9D1-AS1 is highly expressed in colorectal cancer. Interfering with VPS9D1-AS1 inhibited the proliferation, invasion and migration of HUVECs. Mechanistically, VPS9D1-AS1 can promote angiogenesis by upregulating VEGFA expression and activating the downstream PI3K/AKT pathway. In addition, CEBPB is a transcription factor of VPS9D1-AS1 predicted by database, and the results of ChIP experiments showed that CEBPB could directly bind to the VPS9D1-AS1 promoter region at the -698 bp to -794 bp site. The results of dual luciferase assay showed that CEBPB could enhance VPS9D1-AS1 promoter activity and promote its transcription. VPS9D1-AS1 can be activated by CEBPB transcription factor and target VEGFA to activate its downstream pathway to promote colorectal cancer angiogenesis, which may suggest that VPS9D1-AS1 is critical for regulating colorectal cancer angiogenesis.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1673-1688"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological characteristics and prognostic outcomes of resectable hepatoid adenocarcinoma of the stomach: insights from a multicenter case-control study.","authors":"Zhi-Yi Xiang, Yu-Ying Hu, Qi Zheng, Wei-Ming Yu, Xing-Chen Liu, Ping Chen, Feng Wu, Jun-Hai Pan, Sheng-Qiang Ji, Li-Hu Gu","doi":"10.62347/DBFO6813","DOIUrl":"https://doi.org/10.62347/DBFO6813","url":null,"abstract":"<p><p>Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC). This multicenter case-control study aimed to elucidate the clinicopathological features and prognosis of patients with resectable HAS. This retrospective study included 1387 GC patients treated at Ningbo No. 2 Hospital between January 2016 and December 2023, among whom 23 were HAS cases and incorporated 61 HAS patients from three external centers. Prognostic factors were analyzed using the Cox proportional hazards model. Propensity score matching (PSM) at a ratio of 4:1 and Kaplan-Meier survival curves were employed for analysis. The prevalence of HAS in this cohort was 1.1%. Among the 84 HAS patients with a median follow-up of 28 months, 47.6% had serum alpha-fetoprotein (AFP) levels exceeding 20 ng/mL. During the follow-up period, 44.0% of patients experienced relapses, predominantly through hepatic metastasis (62.2%). Univariate and multivariate analyses identified preoperative serum AFP levels between 200-500 ng/mL and TNM stages III/IV as independent prognostic factors for overall survival (OS). Elevated preoperative levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and TNM stages III/IV were independently associated with poorer disease-free survival (DFS). Conversely, open surgery and a Ki-67 proliferation index exceeding 50% were found to act as protective factors for both OS and DFS, with postoperative chemotherapy improving OS outcomes. After PSM adjustment, the analysis included 248 non-HAS patients and 62 HAS patients, revealing significantly better OS (P=0.043) and DFS (P=0.009) among non-HAS patients. Open radical surgery followed by adjuvant chemotherapy is recommended for the treatment of resectable HAS. Overall, patients with HAS exhibit a less favorable prognosis compared to those with non-HAS.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1689-1704"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of behavioral activation in reducing fear of cancer recurrence in non-small cell lung cancer patients: a randomized controlled trial.","authors":"Han Ge, Anlong Li, Runze Huang, Chen Gan, Yingxue Jia, Jiaying Chai, Lijun Liu, Xinyi Zheng, Jian Xu, Mingjun Zhang, Huaidong Cheng","doi":"10.62347/ZSKM4538","DOIUrl":"https://doi.org/10.62347/ZSKM4538","url":null,"abstract":"<p><p>Fear of cancer recurrence (FCR) is a significant risk factor affecting treatment outcomes and prognosis in non-small cell lung cancer (NSCLC) survivors. Behavioral activation (BA), a structured therapeutic approach based on cognitive-behavioral therapy (CBT) principles, has demonstrated efficacy in alleviating psychological distress among cancer patients. This study aims to investigate the effect of BA on FCR in patients with NSCLC and explore the underlying mechanisms. A total of 82 eligible patients were randomly assigned to either the intervention group (BA) (n = 41) or the usual care group (CAU) (n = 41). Assessments were conducted at baseline (T0), week 4 (T1), and week 8 (T2) using the Cancer Recurrence Fear Scale-Brief Form (FCRI-SF), the Hospital Anxiety and Depression Scale (HADS), the Brief Resilient Coping Scale (BRCS), and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0. Negative emotions (depression and anxiety), as well as resilient coping, were identified as potential mediators. The intervention effect and its potential mediating effects were analyzed using generalized estimating equations (GEE). GEE analysis revealed significantly lower FCR scores in the BA group at weeks 4 and 8 (Group*T1: Wald X² = 25.79, P < 0.001; Group*T2: Wald X² = 59.59, P < 0.001). Depression and anxiety scores decreased over time in the BA group and remained consistently lower than those in the usual care group (depression: Group*T1 Wald X² = 34.67, P < 0.001; Group*T2 Wald X² = 56.05, P < 0.001; anxiety: Group*T1 Wald X² = 36.22, P < 0.001; Group*T2 Wald X² = 64.85, P < 0.001). Scores for resilient coping and quality of life increased over time in the BA group and were significantly higher than those in the usual care group (resilient coping: Group*T1 Wald X² = 19.49, P < 0.001; Group*T2 Wald X² = 66.19, P < 0.001; quality of life: Group*T1 Wald X² = 19.86, P < 0.001; Group*T2 Wald X² = 64.46, P < 0.001). Furthermore, negative emotions (depression and anxiety), as well as resilient coping, were found to mediate the effect of BA on changes in FCR. The BA intervention can alleviate FCR symptoms and improve the quality of life in NSCLC patients by reducing negative emotions (depression and anxiety) and enhancing resilient coping.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1806-1819"},"PeriodicalIF":3.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}